SUPN News & Events

Tech was at the forefront of Tuesday's rebound from Monday's deep selloff, and while AMDwas especially strong in the wake of its $100B deal with Metaannounced this morning, Enterprise Software also snapped higher following yesterday's spasm brought on by the viral Citrini Research post about AI disruption of legacy networks.  Adobeand Salesforce- down 27% and 30% respectively year-to-date - rebounded by 3.4% and 4.1% in Tuesday's trading.  Conversely, Energy and Health Care - two sectors that saw some inflows overnight - were negative on the day.   In the opening hour of the evening session and heading into this evening's State of the Union address by President Trump, index futures are flat.Commodities are also little changed, with WTI Crude Oil still above $66 per barrel despite the large API inventories build.  Precious metals are off their highs due to a rebound in the dollar - Gold is just north of $5,160 while Silver has retreated to $87 per ounce.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Axon Enterpriseup 15.3%Flywireup 10.6%Everus Constructionup 10.0%Resideo Technologiesup 9.7%Cava Groupup 8.6%TransMedicsup 6.9%CCC Intelligent Solutionsup 6.5%Trex Companyup 6.1%Supernus Pharmaceuticalsup 4.7%DOWN AFTER EARNINGS -Camping Worlddown 12.4%First Solardown 12.3%Workdaydown 9.0%GoDaddydown 7.9%CoStar Groupdown 6.6%HP Inc.down 6.3%Talos Energydown 5.6%MercadoLibredown 5.3%Lucid Groupdown 5.0%Tempus AIdown 4.4%

Full year 2026 guidance for total revenues of $840 million to $870 million, operating earnings of $0 million to $30 million, and adjusted operating earnings of $140 million to $170 million.

Reports Q4 revenue $211.6M, consensus $195.16M. "We made significant progress in 2025 against our strategic objectives, with record total revenues, including strong growth in combined revenues of our growth products, the successful acquisition of Sage Therapeutics, Inc., and the U.S. Food and Drug Administration's approval and launch of ONAPGO for Parkinson's disease," said Jack Khattar, President and CEO of Supernus. "In 2026, we are focused on continued progress of our key growth products, including resumption of new patient initiation for ONAPGO, while advancing our pipeline of promising therapeutic candidates."